fda2outsideweb

FDA advisory panel backs TB Alliance’s tuberculosis regimen

pharmafile | June 10, 2019 | News story | Sales and Marketing |  FDA, TB Alliance, US, pharma, tuberculosis 

An FDA advisory panel has voted to recommend the investigational drug pretomanid, developed by the non-profit organisation TB Alliance, as a therapy for extensively drug-resistant tuberculosis and treatment-intolerant or non-responsive multidrug-resistant (MDR) tuberculosis, when combined with a regimen of bedaquiline and linezolid.

The US regulator’s Antimicrobial Drugs Advisory Committee voted 14-4 in favour of authorising the drug regimen for application in the US. The panel agreed that there was “substantial evidence of the effectiveness and sufficient evidence of the safety of pretomanid as part of a combination regimen with bedaquiline and linezolid” in the treatment of the condition.

The panel’s decision was made based on aggregated data from 19 clinical studies investigating the safety and efficacy of the pretomanid regimen, one of which incdicated that it achieved a favourable outcome in 90% of patients after six months of treatment and six months of post-treatment follow-up.

“We are encouraged by the advisory committee’s vote in favour of pretomanid for use in combination with bedaquiline and linezolid for the treatment of highly-resistant forms of TB and we look forward to the FDA’s final action,” remarked Mel Spigelman, President and CEO of TB Alliance.

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cell therapy partnership aims to bring liver disease treatment closer to US patients

Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …

The Gateway to Local Adoption Series

Latest content